Steve Roome, Commercial Director for Ascent Scientific, comments, “This groundbreaking tool provides a means for scientists to optically measure important presynaptic processes at the synaptic terminal level of discrete neurons."
New York, NY and Bristol, UK (PRWEB) February 14, 2010
Columbia University and Ascent Scientific announced that they have entered into a license agreement for FFN511, a novel fluorescent probe for optical imaging and measurement of synaptic activity in the brain.
Memory, decision making and learning require activation and modification of synapses in the brain. This synaptic transmission involves the accumulation of neurotransmitters in vesicles within the cytoplasm of the pre-synaptic neuron; neurotransmitters are then released when the vesicle fuses with the plasma membrane of the cell. Previous methods have allowed researchers to measure post-synaptic neuronal activity and to observe the vesicle-membrane fusion process but, until now, it has not been possible to observe actual neurotransmitter release from individual synapses.
Born of the need for a tool that would permit direct visualization of neurotransmitter release and uptake, and measurement of synaptic activity, the laboratories of Dalibor Sames, PhD, an Associate Professor in Columbia’s Department of Chemistry, and David Sulzer, PhD, a Professor of Neurobiology at Columbia University Medical Center, collaborated to create several Fluorescent False Neurotransmitters (FFNs), a class of highly efficient optical imaging probes that fluoresce sufficiently enough to provide resolution at the individual synaptic level but at concentrations that do not interfere with normal synaptic function.
Steve Roome, Commercial Director for Ascent Scientific, comments, “This groundbreaking tool provides a means for scientists to optically measure important presynaptic processes at the synaptic terminal level of discrete neurons. We are delighted to be the first commercial supplier to bring FFN511 to the life sciences community.”
Dr. Sames reports, “In our recent Science publication, we describe a new form of synaptic plasticity, revealed by FFN511, where individual dopaminergic synapses respond differently to stimulus frequency (which emulates brain activity). FFN511 enabled us to acquire optical measurements of presynaptic changes, at a spatial resolution up to one micromolar, that were simply not possible to achieve with existing probes or electrophysiological methods.”
“We believe that FFN511 has the potential to become an essential research tool for neuroscientists studying the synaptic transmission of dopamine as well as for drug discovery efforts seeking to identify improved blockers and enhancers of dopamine transporter activity,” says Dr. Sulzer. “Blocking of dopamine active transport proteins has been shown to ameliorate symptoms in pre-clinical models of Parkinson’s Disease, and drugs that target dopamine transporters and receptors are used to treat ADHD, bipolar disorder and schizophrenia.”
“Broadly, FFNs provide a means of characterizing neurotransmitter release at the level of individual synapses, even on the same neuron. This capability is very important for understanding how the nervous system activates specific pathways and actions, and how it is altered by learning and development,” explains Beth Kauderer of Columbia Technology Ventures, the technology licensing office of Columbia University. “We expect that FFNs will be useful for both fundamental and applied neurobiology research, across a wide range of areas including learning, neurodegeneration and drug addiction.”
Gubernator et al (2009). Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals. Science 324(5933):1441-4.
About Columbia Technology Ventures
A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia’s intellectual property portfolio and serves as the university’s gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit http://www.techventures.columbia.edu.
About Ascent Scientific
Ascent Scientific offers a range of high quality receptor ligands and synthetic chemistry services at competitive prices. Our Low-Cost LigandsTM range of products includes receptor ligands and signaling tools for research in areas such as glutamate, GABA, ion channels, cannabinoids, opioids, 5-HT and more. We also offer cost-effective custom synthesis of a wide range of chemical entities, including organic molecules, fluorescent labels, standards & references, stable isotope labels, and receptor ligands. To request a new catalogue, visit our website http://www.ascentscientific.com, or contact customer service at firstname.lastname@example.org.
+44 (0)117 982 9988
steveroome (at) ascentscientific (dot) co.uk
Columbia Technology Ventures
techventures (at) columbia (dot) edu